Achilles Therapeutics Company
Achilles Therapeutics is a developer of immunotherapies intended to offer next-generation, patient-specific therapies to treat cancer.
Investors
Technology:
CAR-T, Cell-based gene therapy
Industry:
End-to-end Drug Development, Healthcare, Public
Headquarters:
London, England, United Kingdom
Founded Date:
2016-05-01
Employees Number:
101-250
Funding Status:
IPO
Investors Number:
15
Total Funding:
212991704
Estimated Revenue:
$10M to $50M
Last Funding Date:
2022-07-21
Last Funding Type:
Grant
Register and Claim Ownership